Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P.

about

The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells.Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.

P2860

Q49302678-CEA1532A-C05E-4E07-A0CB-567E78E4079A Q55506772-5D0DA160-38E1-414F-9CE2-4158AF1EFE34

P2860

Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P.

Item

http://www.wikidata.org/entity/Q41549134

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Micro-HCCs in rats with liver ...... ascular disrupting agent CA4P.

@en

type

Item

label

Micro-HCCs in rats with liver ...... ascular disrupting agent CA4P.

@en

prefLabel

Micro-HCCs in rats with liver ...... ascular disrupting agent CA4P.

@en

P1476

Micro-HCCs in rats with liver ...... ascular disrupting agent CA4P.

@en

P2093

Feng Chen

http://www.w3.org/2001/XMLSchema#string

Frederik De Keyzer

http://www.w3.org/2001/XMLSchema#string

Gang Huang

http://www.w3.org/2001/XMLSchema#string

Guy Bormans

http://www.w3.org/2001/XMLSchema#string

Jian Zhang

http://www.w3.org/2001/XMLSchema#string

Jianjun Liu

http://www.w3.org/2001/XMLSchema#string

Jie Yu

http://www.w3.org/2001/XMLSchema#string

Johan Swinnen

http://www.w3.org/2001/XMLSchema#string

Raymond Oyen

http://www.w3.org/2001/XMLSchema#string

Shaoli Song

http://www.w3.org/2001/XMLSchema#string

P2860

Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research

Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI

Phase I trial of combretastatin a-4 phosphate with carboplatin.

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Histopathology of hepatocellular carcinoma

Quantitative proton MR spectroscopy as a biomarker of tumor necrosis in the rabbit VX2 liver tumor.

Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.

Disrupting tumour blood vessels.

P304

55204-55215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.19339

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Uwe Himmelreich

P577

2017-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28903414

http://www.w3.org/2001/XMLSchema#string

P932

5589653

http://www.w3.org/2001/XMLSchema#string

Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P.

about

P2860

P2860

Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932